MACK Merrimack Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MACK

Price (delayed)

$12.62

Market cap

$180.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.1

Enterprise value

$174.65M

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® ...

Highlights
MACK's equity is up by 43% YoY
MACK's net income is up by 10% since the previous quarter and by 6% year-on-year
MACK's quick ratio is up by 31% year-on-year but it is down by 17% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.merrimackpharma.com
Peers: GERN CHRS RGEN

Key stats

What are the main financial stats of MACK
Market
Shares outstanding
14.32M
Market cap
$180.73M
Enterprise value
$174.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$1.43M
EBITDA
-$1.43M
Free cash flow
-$1.41M
Per share
EPS
-$0.1
Free cash flow per share
-$0.1
Book value per share
$1.31
Revenue per share
$0
TBVPS
$1.35
Balance sheet
Total assets
$19.3M
Total liabilities
$493,000
Debt
$0
Equity
$18.81M
Working capital
$18.8M
Liquidity
Debt to equity
0
Current ratio
39.14
Quick ratio
38.34
Net debt/EBITDA
4.25
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-7.3%
Return on equity
-7.5%
Return on invested capital
-27%
Return on capital employed
-7.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MACK stock price

How has the Merrimack Pharmaceuticals stock price performed over time
Intraday
-0.79%
1 week
-1.48%
1 month
2.77%
1 year
5.96%
YTD
10.12%
QTD
2.35%

Financial performance

How have Merrimack Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
$46,000
Net income
-$1.43M
Gross margin
N/A
Net margin
N/A
The operating income has surged by 142% since the previous quarter but it has dropped by 88% year-on-year
MACK's net income is up by 10% since the previous quarter and by 6% year-on-year

Growth

What is Merrimack Pharmaceuticals's growth rate over time

Valuation

What is Merrimack Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Merrimack Pharmaceuticals's EPS has increased by 9% from the previous quarter and by 9% YoY
The price to book (P/B) is 104% higher than the 5-year quarterly average of 4.7 and 8% higher than the last 4 quarters average of 8.9
MACK's equity is up by 43% YoY

Efficiency

How efficient is Merrimack Pharmaceuticals business performance
Merrimack Pharmaceuticals's return on invested capital has surged by 99% YoY and by 64% QoQ
MACK's ROE is up by 32% YoY and by 17% from the previous quarter
The company's return on assets rose by 32% YoY and by 17% QoQ

Dividends

What is MACK's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Merrimack Pharmaceuticals financials performed over time
MACK's total assets is up by 42% YoY
MACK's quick ratio is up by 31% year-on-year but it is down by 17% since the previous quarter
The debt is 100% less than the equity
MACK's equity is up by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.